SAN DIEGO--(BUSINESS WIRE)--
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid
point-of-care diagnostic tests, today announced that it will present at
the 27th Annual J.P. Morgan Healthcare Conference to be held
at the Westin St. Francis Hotel in San Francisco on January 12-15, 2009.
Caren Mason, president and chief executive officer, and John Radak,
chief financial officer, will present on Thursday, January 15, 2009 at
3:30 p.m. Eastern time (12:30 p.m. Pacific time).
A webcast and audio archive of the presentation will be available via
the Investor Relations section of the Company's Web site at www.quidel.com.
Participants should allow approximately five to ten minutes prior to the
presentation's start time to visit the site and download any streaming
media software needed to listen to the Internet webcast. A replay of the
webcast will also be available on the Company’s Web site for 90 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people
around the globe through the discovery, development, manufacturing and
marketing of rapid diagnostic solutions at the point of care (POC) in
infectious diseases and reproductive health. Marketed under the leading
brand name of QuickVue®, Quidel's portfolio of products currently
includes tests that aid in the diagnosis of several disease or condition
states, including influenza, respiratory syncytial virus, Fecal Occult
Blood, Strep A, pregnancy, bacterial vaginosis, H. pylori and Chlamydia.
Quidel's products are sold to healthcare professionals with a focus on
the physician office lab and acute care markets through leading medical
distribution partners on a worldwide basis. Quidel's Specialty Products
Group (SPG) develops research products in the fields of oncology and
bone health with potential future point-of-care applications. By
building value in rapid diagnostic tests, Quidel provides leadership to
the industry and among healthcare professionals allowing for the
movement of patient testing out of the central laboratory setting and
into the physician office, urgent care and other outpatient settings
where rapid testing and treatment has an impact on clinical outcomes and
provides an economic benefit. For more information, visit www.quidel.com,
Source: Quidel Corporation
John M. Radak, Chief Financial Officer
Novelli Life Sciences